Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
New short expert interviews from EAU 2016, Munich, Germany, 11-15 March
Highlights from EAU and expert opinion on new guidelines and developments in advanced prostate cancer
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Karim Fizazi, Kim N. Chi, Johann S. de Bono, Leonard G. Gomella, Kurt Miller, Dana E. Rathkopf, Charles J. Ryan, Howard I. Scher, Neal D. Shore, Peter De Porre, Anil Londhe, Tracy McGowan, Nonko Pelhivanov, Robert Charnas, Mary B. Todd, Bruce Montgomery
Eur Urol. 2016 Mar 7. doi: 10.1016/j.eururo.2016.02.035. [Epub ahead of print]
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Christopher P. Evans, Celestia S. Higano, Thomas Keane, Gerald Andriole, Fred Saad, Peter Iversen, Kurt Miller, Choung-Soo Kim, Go Kimura, Andrew J. Armstrong, Cora N. Sternberg, Yohann Loriot, Johann de Bono, Sarah B. Noonberg, Hank Mansbach, Suman Bhattacharya, Frank Perabo, Tomasz M. Beer, Bertrand Tombal
Eur Urol. 2016 Mar 19. doi: 10.1016/j.eururo.2016.03.017. [Epub ahead of print]
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study
Sun Y, Zou Q, Sun Z, Li C, Du C, Chen Z, et alInt J Urol 2016 May;23(5):404-11.
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration resistant prostate cancer: Results from PREVAIL
Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TWAnn Oncol. 2016 Feb;27(2):286-94
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al.Lancet Oncol 2016 Feb;17(2):153-63.
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.